

SUPPLEMENTARY MATERIAL

Effect of GLP-1 receptor agonists on major cardiovascular outcomes: a systematic review and meta-analysis

Muhammad Furqan Saleem,^{1*} Amen Mansoor,^{2*} Eman Shahid,³ Muskan Lohana,⁴
Muhammad Saqib Ghafoor,⁵ Muhammad Usman Khan,⁶ Faizan Abbas,⁷ Het Hirpara,⁸
Ayesha Khalid,⁵ Furqan Hassan,⁹ Mohammad Ebad Ur Rehman,¹⁰
Danial Rizwan,¹¹ Ameen M. Mohammad,¹² Vaibhav Vats¹³

*These authors are joint first authors

¹Department of Cardiology, Loma Linda University Medical Center, California, USA; ²Department of Internal Medicine, University Hospital of Morecambe Bay NHS Foundation Trust, United Kingdom; ³Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan; ⁴Department of Medicine, Liaquat University Hospital, Jamshoro, Pakistan; ⁵Department of Medicine, King Edward Medical University, Lahore, Pakistan; ⁶Department of Medicine, Sahiwal Medical College, Sahiwal, Pakistan; ⁷Department of Medicine, Fatima Memorial Hospital, Lahore, Pakistan; ⁸Department of Medicine, C. U. Shah Medical College, Gujarat, India; ⁹Department of Medicine, Nishtar Medical University, Multan, Pakistan; ¹⁰Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan; ¹¹Geisinger Health System, Wilkes-Barre, Pennsylvania, USA; ¹²Department of Internal Medicine, College of Medicine, University of Duhok, Iraq; ¹³Department of Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, New York, USA


Correspondence: Mohammad Ebad Ur Rehman, Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan, 46000.

Tel: +923365367865. E-mail: ebadrehman.rehman@gmail.com


Key words: glucagon-like receptor, major adverse cardiovascular events, myocardial infarction.

Study ID	D1	D2	D3	D4	D5	Overall	
Kosiborod 2023	+	+	+	+	+	+	Low risk
Pfeffer 2015	+	+	+	+	+	+	Some concerns
Marso 2016	+	+	+	!	+	!	High risk
Hernandez 2018	+	+	+	+	+	+	
Gerstein 2019	+	+	+	+	+	+	D1 Randomisation process
Lincoff 2023	+	+	+	+	+	+	D2 Deviations from the intended interventions
Ruff 2022	+	+	+	+	+	+	D3 Missing outcome data
Gerstein 2021	!	+	+	+	+	!	D4 Measurement of the outcome
Marso 2020	+	+	+	+	+	+	D5 Selection of the reported result
Husain 2019	+	+	+	+	+	+	
Holman 2022	+	+	+	+	+	+	
Margulies 2016	+	+	+	+	+	+	


Supplementary Figure 1. Risk of bias in randomized controlled trials.




Supplementary Figure 2. Forest plot of all-cause mortality.




Supplementary Figure 3. Forest plot of myocardial infarction.




Supplementary Figure 4. Forest plot of fatal myocardial infarction.




Supplementary Figure 5. Forest plot of non-fatal myocardial infarction.




Supplementary Figure 6. Forest plot of stroke.




Supplementary Figure 7. Forest plot of fatal stroke.




Supplementary Figure 8. Forest plot of non-fatal stroke.



Supplementary Figure 9. Forest plot of heart failure hospitalization.



Supplementary Figure 10. Forest plot of unstable angina hospitalization.



Supplementary Figure 11. Forest plot of revascularization.

Supplementary Table 1. Detailed search strategy.

Database	Search Strategy
PubMed	("Glucagon-Like Peptide-1 Receptor Agonists"[Mesh] OR Glucagon Like Peptide 1 Receptor Agonists OR GLP-1 Agonists OR Agonists, GLP-1 OR GLP 1 Agonists OR GLP-1 Receptor Agonists OR GLP 1 Receptor Agonists OR GLP1 Agonists OR Agonists, GLP1 OR GLP-1R Agonists OR Agonists, GLP-1R OR GLP 1R Agonists OR Glucagon Like Peptide 1 Receptor Agonists OR GLP-1 Agonists OR Agonists, GLP-1 OR GLP 1 Agonists OR GLP-1 Receptor Agonists OR GLP 1 Receptor Agonists OR GLP1 Agonists OR Agonists, GLP1 OR GLP-1R Agonists OR Agonists, GLP-1R OR GLP 1R Agonists OR GLP1R Agonists OR Agonists, GLP1R OR Incretin Mimetics OR GLP-1 Analogs OR GLP 1 Analogs OR GLP1R Agonists OR Agonists, GLP1R OR Incretin Mimetics OR GLP-1 Analogs OR GLP 1 Analogs) AND ("Cardiovascular Diseases"[Mesh] OR Cardiovascular Disease OR Disease, Cardiovascular OR Cardiac Events OR Cardiac Event OR Event, Cardiac OR Adverse Cardiac Event OR Adverse Cardiac Events OR Cardiac Event, Adverse OR Cardiac Events, Adverse OR Major Adverse Cardiac Events)